As of 2024-12-13, the Intrinsic Value of GT Biopharma Inc (GTBP) is
-108.03 USD. This GTBP valuation is based on the model Peter Lynch Fair Value.
With the current market price of 2.74 USD, the upside of GT Biopharma Inc is
-4,042.59%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
-108.03 USD
Intrinsic Value
GTBP Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| Fair Value |
-108.03 - -108.03 |
-108.03 |
-4,042.59% |
| P/E |
(120.47) - (132.22) |
(117.53) |
-4389.5% |
| DDM - Stable |
(26.48) - (95.35) |
(60.92) |
-2323.2% |
| DDM - Multi |
(18.66) - (54.58) |
(28.07) |
-1124.6% |
GTBP Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
6.11 |
| Beta |
1.07 |
| Outstanding shares (mil) |
2.23 |
| Enterprise Value (mil) |
-0.31 |
| Market risk premium |
4.60% |
| Cost of Equity |
11.75% |
| Cost of Debt |
5.00% |
| WACC |
7.71% |